Biocytogen Launches "Nano 100 Project" to Develop Fully Human Nanobody Therapeutics for Over 100 Targets2
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced the launch of the “Nano 100 Project”, which aims to develop fully human nanobody drugs for over 100 targets.
United States Baden Wüberg Haimen Jiangsu Yuelei Shen Biocytogen Pharmaceuticals Beijing Co Ltd Project Integrum
Source: businesswireindia.com